NeuroTheranostics General is structured around development of a therapeutic technology structured around the maintainance and stabilization of casualities/patients with moderate-severe Traumatic Brain Injury. The company's technology characterizes the stability, brain availability, and pharmacokinetic/pharmacodynamic profiles of an intranasally administered selective calpain inhibitor-based therapeutic to maintain moderate to severe TBI, enabling healthcare professionals to enhance neuronal plasticity and improve functional outcomes
